Genprex Inc (GNPX) USD0.001

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.